A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib in Patients With Relapsed of Refractory Multiple Myeloma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2016
Price : $35 *
At a glance
- Drugs Trametinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Apr 2016 Status changed from recruiting to withdrawn prior to enrolment a the PI left institution, according to ClinicalTrials.gov record.
- 27 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.